GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
about
Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAAAstrocytic TDP-43 pathology in Alexander diseaseWhite matter astrocytes in health and disease.Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.Characterization of a panel of monoclonal antibodies recognizing specific epitopes on GFAP.Finding degrees of separation: experimental approaches for astroglial and oligodendroglial cell isolation and genetic targetingNeuronal transgene expression in dominant-negative SNARE miceEnhancement of Colorimetric Response of Enzymatic Reactions by Thermally Evaporated Plasmonic Thin Films: Application to Glial Fibrillary Acidic Protein.Lithium Decreases Glial Fibrillary Acidic Protein in a Mouse Model of Alexander Disease.Elevated GFAP induces astrocyte dysfunction in caudal brain regions: A potential mechanism for hindbrain involved symptoms in type II Alexander disease.Microwave-accelerated bioassay technique for rapid and quantitative detection of biological and environmental samples.CSF and Blood Levels of GFAP in Alexander DiseaseEnhancement of the Chemiluminescence Response of Enzymatic Reactions by Plasmonic Surfaces for Biosensing Applications.Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation.The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.Review on intermediate filaments of the nervous system and their pathological alterations.Glial fibrillary acidic protein exhibits altered turnover kinetics in a mouse model of Alexander disease.Lessons from Animal Models of Cytoplasmic Intermediate Filament Proteins.Aggregation-prone GFAP mutation in Alexander disease validated using a zebrafish model.Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease.
P2860
Q28239546-AA417B4B-50CC-404F-8FEF-A78360331552Q33575134-249927E0-7D34-44A8-BA4D-0188E87AB716Q33594651-64FD0510-4E70-4CFB-94B9-13BC4DE74EB5Q33622527-6061BCCA-CB17-4F78-868A-2287A49EE9B9Q33888244-B7B1D033-571D-4D7A-9716-04DDD8DF1CEEQ34224054-587A1635-1DC1-4C04-822B-BF0123B7E10AQ34664201-2ED4125E-A1FD-4627-A870-E46C28167C84Q35052998-5B06DD70-13EB-43E1-A03E-A1CDAA52BB4CQ35778386-E21A11C5-2412-40BC-AA8B-7E8CFCB14208Q36014767-6658265A-F258-4BE1-9E26-43E111E7BE4FQ36093532-6195AA16-2A6C-4109-B55A-D321A19D3BC5Q36154360-30C7ECF4-082B-40C8-AFBB-BE5D4DE48169Q36283985-EBC212ED-BBC6-4BBF-B93D-26523D049EF3Q37323740-86069A69-608F-405D-892D-E160EA04EEF0Q37503447-23C9342D-D826-43EC-BFA0-B3396B6B5718Q38113164-B1CDED82-359E-43CB-ABB5-1BC3A6447559Q38754750-EF89BE25-ECAE-43DD-BD08-A7A83495921DQ39094595-3FC99408-8488-4822-AA67-3CEA51D15FADQ41523783-A1D93D73-716B-40D7-9108-CF6F5DA37836Q47308800-D13FBAAA-75AC-43E8-8570-A5B84CA43DB0
P2860
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@ast
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@en
type
label
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@ast
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@en
prefLabel
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@ast
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@en
P2093
P2860
P356
P1433
P1476
GFAP expression as an indicator of disease severity in mouse models of Alexander disease.
@en
P2093
Albee Messing
Paige L Jany
Tracy L Hagemann
P2860
P304
P356
10.1042/AN20130003
P577
2013-01-01T00:00:00Z